Navigation Links
Cardiogenesis Reports Third Quarter 2010 Results
Date:11/3/2010

IRVINE, Calif., Nov. 3, 2010 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (OTCQB: CGCP), a leading developer of surgical products used in the treatment of diffuse coronary artery disease, today reported financial results for its third quarter and first nine months ended September 30, 2010.

Revenue for the third quarter of 2010 was $2,764,000, a 30% increase from prior year third quarter revenue of $2,134,000.  Gross margin was 84% for the quarter, two percentage points above the third quarter of 2009.  The company reported a net loss of $154,000, or $0.00 per basic and diluted share, in the third quarter of 2010 as compared with a net loss of $739,000, or $0.02 per basic and diluted share, in the prior year third quarter.

"We experienced strong demand for our disposable handpieces resulting in $2.15 million in revenue in the quarter. Capital equipment sales were also solid which contributed to the increase in sales over last year. Moreover, for the first nine months of 2010 we recorded a 17% year over year increase in disposable handpiece revenue, which is a testament to our ability to increase utilization," said Cardiogenesis Executive Chairman Paul McCormick.  "In addition to success with our commercial products, we are making significant progress on our clinical and regulatory initiatives while financing them through operations.  We started the requisite biocompatibility and animal safety studies at the Texas Heart Institute and in addition, we enrolled the first two patients in our PHOENIX™ Combination Delivery System clinical feasibility trial.  Upon completion, we plan to submit the results from these studies to the U.S. FDA to obtain regulatory clearance to begin the pivotal trial for the PHOENIX System.  The PHOENIX System combines the intramyocardial delivery of stem cells with pre-treatment by TMR. PHOENIX represents an exciting proprietary growth opportunity for our Company."

For the first
'/>"/>

SOURCE Cardiogenesis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
2. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
3. Cardiogenesis Reports Third Quarter 2009 Results
4. Cardiogenesis Corporation to Present at Noble Financial - ONTRACK 2010
5. Cardiogenesis (CGCP) Listing Upgraded to New OTCQB(TM) Market for All U.S. Registered and Reporting OTC Securities
6. Cardiogenesis Corporation to Report 2010 Second Quarter Results on August 4th
7. Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online
8. Cardiogenesis Enrolls First Two Patients in Its Feasibility Study of the PHOENIX® Combination Delivery System
9. Cardiogenesis Corporation to Report 2010 Third Quarter Results on November 3rd
10. Cardiogenesis Receives Research Award From Federal Government
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 /PRNewswire/ ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting ... Under the terms of the collaboration, Foundation ... laboratory component of Foundation Medicine,s FoundationOne® assay at the ...
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
(Date:10/20/2014)... ENGLEWOOD, Colo. , Oct. 20, 2014 /PRNewswire/ ... Inc. (NYSE MKT: AMPE), today announced that its ... the clinical and research potential for its novel ... oxidation-reduction potential (ORP) in the body in response ... clinical value of ORP as a clinical marker ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... 12 Crux Biomedical® was named one of "50 Companies to ... survey, conducted by Medical Device and Diagnostics Industry (MD+DI), was published in ... to identify firms that have either achieved success or have the potential ... , , ...
... , BELOIT, Wis. , July 12 Sheffield ... and excipient products for the biotech and pharmaceutical markets, has been ... , , ... Award recognizes Sheffield Bio-Sciences, consistent execution of quality and services for ...
Cached Medicine Technology:Crux Biomedical Named One of Top 50 Companies to Watch 2Sheffield Bio-Science Wins 2010 Lilly Global Supplier Award 2
(Date:10/22/2014)... Isabel Healthcare will participate in ... Conference on October 22-24 in Las Vegas, NV. Jason ... panel discussion on Technology in Health Professions Education – ... diagnostic decision support tool and clinical education platform designed ... and clinical learners. The Isabel tools help clinicians broaden ...
(Date:10/22/2014)... The Louis W. Sullivan ... to distribute health information technology innovation to transform ... the development of six key guiding principles of ... healthcare. These are an expansion of the Institute ... that is respectful of and responsive to individual ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... 22, 2014 Akeso Biomedical, Inc. ... the treatment of bacterial infections, microbial biofilms, and chronic ... its board of directors. , Dr. Sinskey ... at The Massachusetts Institute of Technology, or MIT. He ... 1968. Dr. Sinskey also holds positions as Co-Director of ...
(Date:10/22/2014)... Salamon HealthDay Reporter TUESDAY, ... conventional in vitro fertilization (IVF) -- the incubation of embryos ... a device inside the vagina, new research suggests. Scientists ... called an INVOcell, might sharply cut costs for pricey IVF ... more accessible to those who don,t live near big-city assisted ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... panels and format for its “OneMedForum 2009” ... 2009, in San Francisco at the Sir ... “drivers and disrupters” affecting each of the ... Nervous System and Neurostimulation; Cardiology; Urology and ...
... Inc.,(OTC Bulletin Board: USFM), a diversified commercial Farming ... (OTCFN), a division of,National Financial Communications Corp. (NFC), ... OTCFN Report details US Farms, Inc.,s current operations,industry ... and,management team. Interested parties can download the ...
... MEETING, Pa., Dec. 4 Genaera Corporation (Nasdaq: ... of Genaera, is scheduled to present at the 2008 RBC ... RBC Capital Markets, panel discussion of obesity, entitled, "Shrinking The ... Square Hotel in New York on Wednesday, December 11 at ...
... from bone marrow may serve as a novel therapeutic option ... characterized by extraordinarily fragile skin, according to a study pre-published ... American Society of Hematology. , , ... fragile skin and blistering on touch, akin to third degree ...
... in Giving as Demand for Nonprofit Services Peaks , ... than half of Coloradans report that they will give the ... economic downturn, according to " Generous Colorado: Why Donors Give ... data from surveys conducted October 2008. With demand for services ...
... purchasing the Green Bracelet at www.simmonsjewelryco.com , ... Empowerment Fund (D.E.F.), Hearst Magazines, and A Diamond is ... Africa" dinner held at Hearst Tower in Manhattan Monday evening ... Simmons and special guests including Tamsin Smith , ...
Cached Medicine News:Health News: OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions 2Health News:OTC Financial Network Issues Corporate Profile on US Farms, Inc. 2Health News:OTC Financial Network Issues Corporate Profile on US Farms, Inc. 3Health News:Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 3Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 4Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 2Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 3Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 4Health News:On World AIDS Day, Russell Simmons and Special Guests Attended 'Empowerment for Africa' Dinner 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: